Physician profile
Mitchell A Cunningham
NPI 1437719952
$225.51
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.78 · 2021: $179 · 2022: $31.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.29 | 2021-2022 | |
| Lundbeck LLC | $29.46 | 2021 | |
| Vanda Pharmaceuticals INC. | $23.41 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.62 | 2022 | |
| Sanofi Pasteur INC. | $14.78 | 2020 | |
| Alfasigma USA, INC. | $14.10 | 2021 | |
| Indivior INC. | $12.85 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.